The stock of Anixa Biosciences, Inc. (NASDAQ:ANIX) hit a new 52-week low and has $3.09 target or 7.00% below today's $3.32 share price.
News
- Anixa Biosciences, Inc. (ANIX) Reaches $3.32 Yearly Low; SMA SOLAR TECHNOLOGY AG ...
- BriaCell Announces Clinical Data as Presented at the 2019 San Antonio Breast Cancer Symposium®
("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapies for ...
- Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended ...
... trial of Puma's drug neratinib at the 2019 San Antonio Breast Cancer Symposium (SABCS) that is currently taking place in San Antonio, Texas.
- Life Science Big News Roundup: Algernon Selects NP-120 for its Lead Phase 2 Trial; BriaCell ...
Life Science Big News Roundup: Algernon Selects NP-120 for its Lead ... Data as Presented at the 2019 San Antonio Breast Cancer Symposium®.
- Recon: Sarepta Wins Early Approval for DMD Drug After Earlier Rejection; PhRMA Sues Over ...
A third DMD approval, analysts predict (Endpoints); Biotech veteran Chris ... Pharmaceutical & Biotechnology: Study Results, Filings & Designations ... Metastatic Triple Negative Breast Cancer (mTNBC) at the 2019 San Antonio ...